Introduction
Many clinical trials and medical studies use periodic scheduled follow-ups of each patient to monitor the time to an event of interest or disease (Le. survival time T of the patient) whose occurrence is not apparent from outside. The occurrence of such event can be detected only through some invasive procedure (such as testing blood or tissue samples etc.) performed during these clinic visits. Medical researchers often come across interval censoring in such studies when the patients miss some of the scheduled appointments for reasons not related to the survival times and the observed censoring intervals containing their survival times frequently overlap with each other. Interval-censored survival data have recently received much attention in biostatistical and statistical literature due to diseases such as AIDS and some forms of cancers. For recent reviews, see Satten (1996) , and Frydman (1995) . The data set in Table 3 of Finkelstein and Wolfe (1985) is a historical data set of interval-censored data. In this data set, 46 early breast cancer patients receiving only radiotherapy (covariate value z = 0) and 48 patients receiving radio-chemotherapy (z = 1) were monitored for cosmetic change during weekly clinic visits. But, some patients missed some of their weekly visits. So, the data on survival time are typically recorded as, for example, (7, 18] (at the 7th week clinic-visit, patient had shown no change and then in the next clinic visit at the 18th week the patient's tissue showed that the change had already occurred).
Since, the clinic visits of different patients occurred at different times, the censoring intervals in the data set are found to be often overlapping.
We are interested to see the effect of the covariate z associated with the patient, on the survival (1996) analyzed interval-censored data under the assumption of Cox model. But, such an assumption of time-independent regression coefficient may not always be valid. The major contribution of the present paper is two fold. With the advancement of the sampling based computational tools, it is now feasible to consider more general models which incorporates time-varying coefficients. Secondly, while powerful computational tools enable us to fit remarkably complex models we should not loose sight of the need to make suitably parsimonious choices. So, we develop some Bayesian tools for model selection and model validation. So far, to our knowledge there is no formal statistical method to select among the models we propose or to check any modeling assumption such as time-independent coefficient for interval-censored data. In addition, Bayesian method enables us to obtain exact small sample inference on the parameter of interest (i.e. the regression coefficient), from the moderate sized data set even with a high-dimensional nuisance parameter (Le., the baseline hazard).
In Section 2, we propose a Bayesian version of discretized Cox model and a model with time-varying coefficients. In Section 3, we describe model fitting using sampling based method. In Section 4, we present some Bayesian model selection and model checking methods. In Section 5, we illustrate the proposed methods by reanalyzing the breast cancer data of Finkelstein and Wolfe (1985) . Section 6 concludes with some remarks. 13Ie's are apriori independent of A .
In above, we assume that the hyperparameters of these models, viz., Tile'S, ile'S, WIe'S and 130 are known in advance.
M o is a discretized version of Cox model with a discretized version of the gamma process prior (Kalbfleisch 1978) for the baseline hazard AOO where TlIe/ile is the prior mean and TlIe/i~is the prior variance of Ale. When the grid intervals are sufficiently small, this discretized version will be indistinguishable from the actual time-continuous gamma process. The discretized autocorrelated prior process for 13Ie's in M 1 allows the covariate effect to change over time, but also incorporates the prior information that the values of the coefficient 13 in adjacent intervals are expected to be somewhat close and the dependence among the 13's decrease as the intervals become further apart. This assumption seems to be in complete accordance with some studies where the covariate effect may change over time, but is not expected to change too wildly over time. The parameters w/c 's· can be used as a tuning device to determine our prior opinion about the possible change in the magnitude of 13 over time. For example, apriori we expect the 131c+1 to be within approximately 1.96wIe from the 131e with 95% confidence. The w/c's should depend on the lengths of the lie's allowing the coefficient to change more for bigger grid intervals. It is possible to use an autocorrelated prior process for the baseline hazard also. For details on the use and properties of an autocorrelated process, see Sinha and Dey (1997), and Sargent (1996) .
Our major interest is to compare the Cox model (M o ) with the time varying coefficient model (Md.
For the example of breast cancer data, we consider following values of the hyperparameters. In practice, these hyperparameters should be chosen to represent a carefully developed prior opinion based on the results from previous studies related to the present experiment. Often in clinical trials setting, scientists conduct multiple studies to investigate single important medical or biological issue.
One advantage of Bayesian method is that it allows us to incorporate the prior expertise into theexperiment. For example, we can use data from previous studies to elicit the prior mean (11le/Ale) and variance (11Ie/A~) of Ale. But in our case, we have chosen the hyperparameters to represent prior opinions which are nearly non-informative (flat) in the subset ofthe parameter space supported by the likelihood.
For example, the common prior mean of Ale'S is taken as 0.5 and the common prior variance is taken as 1.25 (Ale> 0) which gives very non-informative prior opinion in the the range (0.1) and it is clear that for this example we expect Ale'S to be less than 1. We have also made some minor simplifications, for example, taking all the Ale'S to be identically distributed.
Model Fitting
Let us denote the observed interval-censored data from n patients, by Y = {(ali' a,.J; Zi: i = 1,2, ... , n}, where survival time Ti for the ith patient is known to be within (ali' a,.J and ali < a"i are two of the grid points (aI, a2,.' .' a g ) but not necessarily consecutive ones. And, Zi is the covariate value for the ith patient. Let X = {Ti' Zi: i = 1,2, ... , n} be the unobserved complete (augmented) data. For notational simplicity, we denote the set of parameters (A'S and j3's) under any model bye, (however the dimension of e depends on the model under consideration). The distribution of Ti given Zi is piecewise exponential and thus the complete-augmented-data likelihood is (3.1) where Rle is the set of patients at risk at ale-I, f:1jle = min(Tj, ale) -ale-I, Die is the set of patients failing in lle = (ale-I, ale], and dle is the number of patients in Die. The observed data likelihood is complicated and the joint posterior distribution is analytically intractable even for Mo.
We employ sampling based methods, in particular, the Gibbs sampler, (see Tanner 1996 for a review) to sample from the joint posterior of e given Y. Gibbs is an iterative algorithm which alternates between (1) generating the augmented survival times (Ti's) from the conditional distribution of Ti's given the we no longer restrict our inference to a set of stringent regularity assumptions (as often needed to obtain asymptotic optimality).
Bayesian Model Selection
In this section, we propose two different model selection approaches using a generalization of the predictive loss of Laud and Ibrahim (1995) The motivation behind the consideration of such a loss function relies on the standard utility ideas as in, e.g., Raiffa and Schlaifar (1961) . The key idea is to replace the experiments (under standard decisiontheoretic set-up) with models and then separately for each model, minimize the psterior expected loss with respect to a to compute .eM and then select the model with minimum.e M value. The action a can be viewed as a "compromise", which we like to be close to Yob.. (a goodness-of-fit property) as well as to y,.ep (predictive property of a) under the model M. When the model is too restrictive, it is difficult to keep a close to Yob.. and when the model is too general it is difficult to keep a close to y,.ep which has higher variability for bigger model. Thus K. can be viewed as a predetermined constant to decide how much emphasis should be given on goodness-of-fit of M compared to its predictive capacity.
The use of squared loss (on the log-scale) is kind of arbitrary. However it may be noted that, under regularity condition as obtained in Gelfand and Ghosh (1995) , squared loss appear as an approximation to more general classes of loss functions. For more details, see Gelfand and Ghosh (1995 Laud and Ibrahim (1995) , which is obtained by letting K. --t 00 (or equivalently l5 --t 1). One attractive feature of this decision theoretic formulation of the model choice criteria (such as L M) is that it extends the usual testing procedures (whish are based on 0-1 type loss functions) to a fairly general class of loss functions. In fact, the LMas proposed above can be used as an analogue for standard LRT statistic (if we replace the mle's in LRT by the corresponding posterior expected values with reasonably flat priors). For more details, see Gelfand and Ghosh (1997) . As a computational remark, it may be noted that the L Mcan be computed easily (as compared to LRT statistic for our models) from the output of the Gibbs sampler and using the fact that [Y"epIYoba] = ![Y"eple]. [eIYoba] de . This is one of the reasons, we prefer to use L Mover LRT statistic to select the "best" model. (i) is, the more the ith observation supports the model M. Gelfand et al. showed 7 that the CPOM(i) can be computed as 
An Illustrative Example: The Breast Cancer Data
In this section, we are reanalyzing the breast cancer data of Finkelstein and Wolfe (1985) . We implement the Gibbs samplers for the two proposed models under consideration. The convergence of the Gibbs samplers are checked by using several diagnostic procedures as recommended by Cowles and Carlin (1996) and after convergence, we generate 10,000 Gibbs iterates for calculating 95% highest posterior density (HPD) intervals of parameters of interest, L'M criteria, the CPO's, and the PML's for the two proposed models. Next, we plot the In (g~g:~~~~) 's versus i in Figure 2 . In Figure 2 , we notice that 84% of log CPO-ratios are positive. Therefore, we conclude that the most of the data points support M o over M 1 , which is consistent with our conclusion from the single summary measures in Table 1 .
Concluding Remarks
In this article, we have presented a method of Bayesian modeling of interval censored data allowing the regression coefficient of the covariate effect under Cox model to change over time. Cox model is a special case of this class of models. Our models can be used with discretized version of different types of prior processes for the baseline hazard, including gamma and other Levy processes and most of the non-Levy processes (e.g. autocorrelated process). The choices for modeling the prior information on the covariate effect are also very large. Bayesian analysis using MCMC is shown to be feasible for such models. We also present, for the first time in literature, two model selection criteria which can be applied even to other types of censoring (including case-1 censored data). We envision that these model selection criteria can be utilized to diverse field of applications including variable selections and comparing between two or more non-nested models, say, discretized Bayesian Cox model and discretized Bayesian proportional odds model. Here we haven't explored the optimal properties of our criteria from any theoretical aspect. However we feel comfortable to use these criteria, as they don't depend on their large-sample properties. 
